# Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)

> **NCT03141671** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 345 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** GnRH
- **DRUG:** Bicalutamide
- **RADIATION:** Salvage radiation
- **DRUG:** Abiraterone
- **DRUG:** Prednisone
- **DRUG:** Apalutamide

## Key facts

- **NCT ID:** NCT03141671
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-11-24
- **Primary completion:** 2025-04-05
- **Final completion:** 2025-12-31
- **Target enrollment:** 345 (ACTUAL)
- **Last updated:** 2024-05-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03141671

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03141671, "Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03141671. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*